Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
2.
Zanotti-Fregonara P, Veronese M, Pascual B, Rostomily RC, Turkheimer F, Masdeu JC. The validity of 18 F-GE180 as a TSPO imaging agent. Eur J Nucl Med Mol Imaging. 2019;46:1205–7.CrossRef
3.
Unterrainer M, Fleischmann D, Vettermann F, Ruf V, Kaiser L, Nelwan D, et al. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18 F-GE-180 PET study. Eur J Nucl Med Mol Imaging. 2019:1–13.
4.
Albert NL, Unterrainer M, Fleischmann D, Lindner S, Vettermann F, Brunegraf A, et al. TSPO PET for glioma imaging using the novel ligand 18 F-GE-180: first results in patients with glioblastoma. Eur J Nucl Med Mol Imaging. 2017;44:2230–8.CrossRef
5.
Unterrainer M, Fleischmann D, Diekmann C, Vomacka L, Lindner S, Vettermann F, et al. Comparison of 18 F-GE-180 and dynamic 18 F-FET PET in high grade glioma: a double-tracer pilot study. Eur J Nucl Med Mol Imaging. 2019;46:580–90.CrossRef
6.
Albert NL, Unterrainer M, Brendel M, Kaiser L, Zweckstetter M, Cumming P, et al. In response to: the validity of 18 F-GE180 as a TSPO imaging agent. Eur J Nucl Med Mol Imaging. 2019;46:1208–11.CrossRef
7.
Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22:191–204.CrossRef
8.
Brendel M, Probst F, Jaworska A, Overhoff F, Korzhova V, Albert NL, et al. Glial activation and glucose metabolism in a transgenic amyloid mouse model: a triple-tracer PET study. J Nucl Med. 2016;57:954–60.CrossRef
9.
Sacher C, Blume T, Beyer L, Peters F, Eckenweber F, Sgobio C, et al. Longitudinal PET monitoring of amyloidosis and microglial activation in a second-generation amyloid-beta mouse model. J Nucl Med. 2019;60:1787–93.CrossRef
10.
Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A, Buckley C, et al. Flutriciclamide (18F-GE180) PET: first-in-human PET study of novel third-generation in vivo marker of human translocator protein. J Nucl Med. 2016;57:1753–9.CrossRef
11.
Feeney C, Scott G, Raffel J, Roberts S, Coello C, Jolly A, et al. Kinetic analysis of the translocator protein positron emission tomography ligand [18 F] GE-180 in the human brain. Eur J Nucl Med Mol Imaging. 2016;43:2201–10.CrossRef
12.
Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol. 1998;49:436–40.CrossRef
13.
Scott J, Brasher P, Sevick R, Rewcastle N, Forsyth P. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947–9.CrossRef
14.
Su Z, Roncaroli F, Durrenberger PF, Coope DJ, Karabatsou K, Hinz R, et al. The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R) PK11195 PET imaging and neuropathology study. J Nucl Med. 2015;56:512–7.CrossRef
15.
Visi E, Hinz R, Punter M, Majid A, Gerhard A, Herholz K. Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study. In: Efficacy and Mechanism Evaluation, No 71 Southampton: NIHR Journals Library; 2020; 2020.
16.
Sridharan S, Raffel J, Nandoskar A, Record C, Brooks DJ, Owen D, et al. Confirmation of specific binding of the 18-kDa translocator protein (TSPO) radioligand [18 F] GE-180: a blocking study using XBD173 in multiple sclerosis normal appearing white and grey matter. Mol Imaging Biol. 2019;21:935–44.CrossRef
17.
Buchert R, Dirks M, Schütze C, Wilke F, Mamach M, Wirries A-K, et al. Reliable quantification of 18F-GE-180 PET neuroinflammation studies using an individually scaled population-based input function or late tissue-to-blood ratio. Eur J Nucl Med Mol Imaging. 2020. https://​doi.​org/​10.​1007/​s00259-020-04810-1.
18.
Cumming P, Burgher B, Patkar O, Breakspear M, Vasdev N, Thomas P, et al. Sifting through the surfeit of neuroinflammation tracers. J Cereb Blood Flow Metab. 2018;38:204–24.CrossRef
19.
Unterrainer M, Vettermann F, Brendel M, Holzgreve A, Lifschitz M, Zähringer M, et al. Towards standardization of 18 F-FET PET imaging: do we need a consistent method of background activity assessment? EJNMMI Res. 2017;7:1–8.CrossRef
20.
Vomacka L, Albert NL, Lindner S, Unterrainer M, Mahler C, Brendel M, et al. TSPO imaging using the novel PET ligand [18 F] GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Res. 2017;7:1–9.CrossRef
21.
Unterrainer M, Fleischmann DF, Lindner S, Brendel M, Rupprecht R, Tonn JC, et al. Detection of cerebrospinal fluid dissemination of recurrent Glioblastoma using TSPO-PET with 18F-GE-180. Clin Nucl Med. 2018;43:518–9.CrossRef
22.
Reinhold JC, Dewey BE, Carass A, Prince JL. Evaluating the impact of intensity normalization on MR image synthesis. Medical Imaging 2019: Image Processing: International Society for Optics and Photonics; 2019. p. 109493H.
Metadata
Title
In response to: Anatomy of 18F-GE180, a failed radioligand for the TSPO protein
Authors
Nathalie L. Albert
M. Unterrainer
L. Kaiser
M. Brendel
F. J. Vettermann
A. Holzgreve
P. Bartenstein
Publication date
01-09-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-020-04885-w

Other articles of this Issue 10/2020

European Journal of Nuclear Medicine and Molecular Imaging 10/2020 Go to the issue

Letter To The Editor & Reply

Reply to Letter to the Editor: “The added benefit of contrast-enhanced CT in the evaluation of incidental FDG-avid colon lesions”

Original Article

A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma

Short Communication

Ventilation/perfusion SPECT/CT findings in different lung lesions associated with COVID-19: a case series

Original Article

Abnormalities at three musculoskeletal sites on whole-body positron emission tomography/computed tomography can diagnose polymyalgia rheumatica with high sensitivity and specificity

Original Article

High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson’s disease cohort

Original Article

Evaluation of improved attenuation correction in whole-body PET/MR on patients with bone metastasis using various radiotracers